Услуга 1

Portfolio analysis & market analytics

Evaluating commercial potential of your portfolio and optimal strategy for Russia and CIS

Услуга 2

Matchmaking for products and companies

Profiling and introducing potential partners

Услуга 3

Market entry services

Product registration, setting up offices, staffing and commercialization of products

Услуга 4

Market Access, GR and state purchases

Customized solutions and regional access

Why you should work with us

We know the industry «inside-out»

All of our employees have years worked in international pharmaceutical companies in managerial positions in Russia, US and Europe in marketing, sales, business development and government relations. We best understand the business environment, opportunities, limitations, requirements and risks. Our reports and services are at international level of quality in terms of content and format.

Read more

We have complete and accurate information for making decisions

We work with many databases and sources, local and global, constantly updated. Our information resources include professionals from the industry — service providers, healthcare officials, patient associations, top level managers within companies. Our staff is multilingual allowing for wide scope of research. We and our partners have established footprint in many geographies.

Read more

We have our own professional network

We know key decision-makers in charge of corporate operation, licensing and partnering. We have access to key opinion leaders in medical and regulatory fields to aid with making decisions about product or technology prospects. We can easily conduct necessary market research, polls and surveys in order to support and justify strategic or tactical business decisions.

Read more

You may find this interesting:

Росздравнадзор рассказал об изменениях в порядке оказания бесплатной медпомощи

Росздравнадзор подготовил Памятку для граждан об изменениях в Программе государственных гарантий бесплатного оказания гражданам медицинской помощи.

FDA отклонило заявку на комбинированную схему лечения ВИЧ-инфекции от ViiV и J&J

Компания ViiV Healthcare («ВииВ Хелскер») объявила о получении от FDA полного ответного письма (CRL) относительно регистрационной заявки на ее экспериментальный препарат cabotegravir в…